Abstract
Although glycated haemoglobin (HbA1c) has become the key biochemical marker of long-term glycaemic control, analytical method-dependent differences in results can occur when haemoglobin variants are present or HbA1c is reduced by decreased red cell survival. When the measured HbA1c level is discordant with the patient's blood glucose measurements and clinical status, fructosamine is an alternative biochemical marker that can provide a more accurate estimate of the glycaemic control and enable clinicians to appropriately manage patients.
Original language | English |
---|---|
Pages (from-to) | 347-349 |
Number of pages | 3 |
Journal | The Medical Journal of Australia |
Volume | 191 |
Issue number | 6 |
DOIs | |
Publication status | Published - 21 Sept 2009 |
Externally published | Yes |